Global quantitative phosphoproteome analysis of human tumor xenografts treated with a CD44 antagonist

Cancer Research

Volumn 72, Issue 17, 2012, Pages 4329-4339

  Weigand, Stefan ^a   Herting, Frank ^a   Maisel, Daniela ^a   Nopora, Adam ^a   Voss, Edgar ^a   Schaab, Christoph ^b,c   Klammer, Martin ^b   Tebbe, Andreas ^b  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

^b EVOTEC AG   (Germany)

^c MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HERMES ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; PHOSPHOPEPTIDE; RG 7356; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL LYSATE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME MODIFICATION; ENZYME PHOSPHORYLATION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LIVER CANCER; MASS SPECTROMETRY; MOUSE; NONHUMAN; PANCREAS CANCER; PHOSPHOPROTEOMIC ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; PROTEOMICS; QUANTITATIVE ANALYSIS; RECEPTOR BINDING; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; COMPUTATIONAL BIOLOGY; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, SCID; NEOPLASMS; PHOSPHOPROTEINS; PROTEOME; PROTEOMICS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865713442     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-0136     Document Type: Article

References (50)

1. Gotte M, Yip GW. Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res 2006;66:10233-7.
2. Afify A, Purnell P, Nguyen L. Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion. Exp Mol Pathol 2009;86:95-100.
3. Louderbough JMV, Schroeder JA. Understanding the dual nature of CD44 in breast cancer progression. Mol. Cancer Res 2011;9:1573-86.
4. Ringel J, Jesnowski R, Schmidt C, Ringel J, Köhler HJ, Rychly J, et al. CD44 in normal human pancreas and pancreatic carcinoma cell lines. Teratog Carcinog Mutagen 2001;21:97-106.
5. Gotoda T, Matsumura Y, Kondo H, Saitoh D, Shimada Y, Kosuge T, et al. Expression of CD44 variants and its association with survival in pancreatic cancer. Jpn J Cancer Res 1998;89:1033-40.
6. Yang GH, Fan J, Xu Y, Qiu SJ, Yang XR, Shi GM, et al. Osteopontin combined with CD44, a novel prognostic biomarker for patients with hepatocellular carcinoma undergoing curative resection. Oncologist 2008;13:1155-65.
7. Liu J, Jiang G. CD44 and hematological malignancies. Cell Mol Immunol 2006;3:359-65.
8. Zöller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 2011;11:254-67.
9. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signaling regulators. Nat Rev Mol Cell Biol 2003;4:33-45.
10. Orian-Rousseau V. CD44, a therapeutic target for metastasizing tumors. Eur J Cancer 2010;46:1271-7.
11. Toole BP, Ghatak S, Misra S. Hyaluronan oligosaccharides as apotential anticancer therapeutic. Curr Pharm Biotechnol 2008;9:249-52.
12. Robertson BW, Bonsal L, Chellaiah MA. Regulation of Erk1/2 activation by osteopontin in PC3 human prostate cancer cells. Mol Cancer 2010;9:260.
13. Corbett TH, Valeriote FA, Demchik L, Lowichik N, Polin L, Panchapor C, et al. Discovery of cryptophycin-1 and BCN-183577: examples of strategies and problems in the detection of antitumor activity in mice. Invest New Drugs 1997;15:207-18.
14. Villen J, Gygi P. The SCX/IMAC enrichment approach for global phosphorylation analysis by mass spectrometry. Nat Protoc 2008;3:1630-8.
15. Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification.Nat Biotechnol 2008;26:1367-72.
16. Cox J, Matic I, Hilger M, Nagaraj N, Selbach M, Olsen JV, et al. A practical guide to the MaxQuant computational platform for SILAC-based quantitative proteomics. Nat. Protoc 2009;4:698-705.
17. Schaab C. Analysis of phosphoproteomics data. Methods Mol Biol 2011;696:41-57.
18. Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P, et al. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 2006;127:635-48.
19. Zhou Y, Cras-Meneur C, Ohsugi M, Stormo GD, Permutt MA. A global approach to identify differentially expressed genes in cDNA (two-color) microarray experiments. Bioinformatics 2007;23:2073-9.
20. Klammer M, Godl K, Tebbe A, Schaab C. Identifying differentially regulated subnetworks from phosphoproteomic data. BMC Bioinformat 2010;11:1-13.
21. da Cruz L, McConkey F, Feng N, Pereira D, Hahn S, Rubinstein D, et al. Clinical development of huARH460-16-2: a therapeutic antibody targeting the CD44 cancer stem cell antigen on high-incidence adenocarcinomas. J Clin Oncol 2008;26:20 suppl.; abstr. 14581.
22. da Cruz L, McConkey F, Feng N, Pereira D, Hahn S, Rubinstein D, et al. Anti-CD44 antibody, ARH460-16-2, binds to human AML CD34+CD38- cancer stem cells and shows anti-tumor activity in an AML xenograft model. AACR Meeting Abstracts 2008;2008:3976.
23. Chaerkady R, Pandey A. Quantitative proteomics for identification of cancer biomarkers. Proteomics Clin Appl 2007;1:1080-9.
24. Andersen JS, Mann M. Functional genomics by mass spectrometry. FEBS Lett 2000;480:25-31
25. Mann M. Functional and quantitative proteomics using SILAC. Nat Rev Mol Cell Biol 2006;7:952-8.
26. Macek B, Mann M, Olsen JV. Global and site-specific quantitative phosphoproteomics: principles and applications. Ann Rev Pharmacol Toxicol 2009;49:199-221.
27. Geiger T, Wisniewski JR, Cox J, Zanivan S, Kruger M, Ishihama Y, et al. Use of stable isotope labeling by amino acids in cell culture as a spikein standard in quantitative proteomics. Nat Protocol 2011;6:147-57.
28. Monetti M, Nagaraj N, Sharma K, Mann M. Large-scale phosphosite quantification in tissues by a spike-in SILAC method. Nat Methods 2011;8:655-8.
29. Iijima Y, Laser M, Shiraishi H, Willey CD, Sundaravadivel B, Xu L, et al. c-Raf/MEK/ERK pathway controls protein kinase C-mediated p70S6K activation in adult cardiac muscle cells. J Biol Chem 2002;277:23065-75.
30. Zhang Y, Dong Z, Nomura M, Zhong S, Chen N, Bode AM, et al. Signal transduction pathways involved in phosphorylation and activation of p70S6K following exposure to UVA irradiation. J Biol Chem 2001;276:20913-23.
31. Shi Y, Hsu JH, Hu L, Gera J, Lichtenstein A. Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6. J Biol Chem 2002;277:15712-20.
32. Heesom KJ, Gampel A, Mellor H, Denton RM. Cell cycle-dependent phosphorylation of the translational repressor eIF-4E binding protein-1 (4E-BP1). Curr Biol 2001;11:1374-9.
33. Mothe-Satney I, Brunn GJ, McMahon LP, Capaldo CT, Abraham RT, Lawrence JC. Mammalian target of rapamycin-dependent phosphorylation of PHAS-I in four (S/T)P sites detected by phospho-specific antibodies. J Biol Chem 2000;275:33836-43.
34. Pan C, Olsen JV, Daub H, Mann M. Global effects of kinase Inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 2009:8:2796-808.
35. Hung MC, Ding Q, Xia W, Liu JC, et al. ERK associates with and primes GSK-3b. Mol Cell 2005;19:159-70.
36. Eldar-Finkelmann H. Glycogen synthase 3: an emerging therapeutic target. Trends Mol Med 2002;8:126-32.
37. Garcia R, Jove R. Activation of STAT transcription factors in oncogenic tyrosine signaling. J Biomed Sci 1998;5:79-85.
38. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10:105-15.
39. Tian ZJ, An W. ERK1/2 contributes negative regulation to STAT3 activity in HSS-transfected HepG2 cells. Cell Res 2004;14:141-7.
40. Chung J, Uchida E, Grammer JC, Blenis J. STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol 1997;17:6508-16.
41. Gu FM, Li QL, Jiang JH, Huang XY, Pan JF, Fan J, et al. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3. World J. Gastroenterol 2011;17:3922-32.
42. Sivera D, Formenti S, Schneider R. Translational control in cancer. Nat Rev Cancer 2010;256:254-66.
43. Waskiewicz AJ, Johnson JC, Penn B, Mahalingam M, Kimball SR, Cooper JA. Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo. Mol Cell Biol 1999;19:1871-80.
44. Pyronnet S, Imataka H, Gingras AC, Fukunaga R, Hunter T, Sonnenberg N. Human eukaryotic translation initiation factor 4G (eIF4G) recruits Mnk1 to phosphorylate eIF4E. EMBO J 1999;18:270-9.
45. Li Y, Yue P, Deng X, Ueda T, Fukunaga R, Khuri F, et al. Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4Ephosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E. Neoplasia 2010;12:848-55.
46. Naor D, Wallach-Dayan SB, Zahalka MA, Sioniv RV. Involvement of CD44, a molecule with a thousand faces in cancer dissemination. Semin Cancer Biol 2008;18:260-7.
47. Skandalis SS, Kozlova I, Engström U, Hellman U, Heldin P. Proteomic identification of CD44 interacting proteins. IUBMB Life 2010;62:833-40.
48. Zhang LS, Ma HW, Greyner HJ, Zuo W, Mummert ME. Inhibition of cell proliferation by CD44: Akt is inactivated and EGR-1 is down-regulated. Cell Prolif 2010;43:385-95.
49. Lee JL, Wang MJ, Chen JY. Acetylation and activation of STAT-3 mediated by nuclear translocation of CD44. J Cell Biol 2009;185:949-57.
50. Hatano H, Shigeishi H, Kudo Y, Higashikawa K. Tobiume K, Takata T, Kamata N. RHAMM/ERK interaction induces proliferative activities of cementifying fibroma cells through a mechanism based on the CD44-EGFR.Lab Invest 2011;91:379-91.